Previous members of the CDC's Advisory Committee on Immunization Practices (ACIP) had documented financial relationships with the pharmaceutical companies whose vaccines they recommended — here is what the primary source disclosures show. These financial and institutional ties between vaccine scientists and the companies that profit from vaccine sales compromised the objectivity and independence of the scientific and regulatory bodies that oversee vaccine safety and policy. In June 2025, all 17 ACIP members were removed by HHS Secretary Robert F. Kennedy Jr. and replaced with new appointees; in April 2026, HHS rewrote the ACIP charter to broaden membership criteria.
Explanation
A conflict of interest in this context occurs when a vaccinologist who holds themselves out as an impartial scientist has received (or expects to receive) substantial financial benefit from pharma companies whose products they evaluate, promote, or vote on. The source identifies several types:
Type
Description
Royalties
Payments from vaccine sales; tied to volume sold
Consulting fees
Direct payments for advisory services
Corporate board seats
Board membership at vaccine manufacturers
Research funding
Grants from companies whose products the researcher studies
Speakers' bureau
Paid to give talks promoting company products
Paid travel
Company-funded trips to conferences worldwide
Endowed chairs
University research positions funded by pharma donations
Served as Pfizer vaccine advisor while simultaneously serving as one of five members on Pfizer's "independent" Data Safety Monitoring Board for the Covid-19 vaccine clinical trial
Cross-examination (2020): admitted she "is working and being paid by Pfizer" while holding the supposedly independent DSMB position
Medical Journals
Three former editors of top medical journals have publicly described pharma's control over the published science:
Richard Horton (The Lancet, 2004): "Journals have devolved into information laundering operations for the pharmaceutical industry."
Richard Smith (British Medical Journal, 25-year editor): "Medical journals are an extension of the marketing arm of pharmaceutical companies."
Marcia Angell (New England Journal of Medicine, former editor): "It is no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines." She reached this conclusion "slowly and reluctantly over my two decades as an editor of the New England Journal of Medicine."
The Structural Problem
Siri's argument is not merely that individual scientists are corrupt, but that the financial structure is self-reinforcing:
Plotkin's career advancement and the financial support he received from pharmaceutical companies were mutually reinforcing — his work shaped vaccine policy in ways that served industry commercial interests, and industry funding sustained his influence over the field.
Scientists whose views aligned with pharma's interests received patronage and ascended. Scientists who did not lost funding and stalled. The result: the entire field of vaccinology leadership consists of people whose career success depended on pharma patronage.
The Marcia Angell Quote
Siri introduced Stanley Plotkin to a quote from Dr. Marcia Angell (Harvard professor, former NEJM editor-in-chief):
> "It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines." She described individuals who "serve as consultants to the same companies whose products they evaluate, join corporate advisory boards and speakers bureaus, enter into patent and royalty arrangements... promote drugs and devices at company-sponsored symposia."
Siri then walked Plotkin through this list, confirming point-by-point that Plotkin fits every element of Angell's description. Plotkin had no choice but to agree.
What types of conflicts of interest do vaccine advisory committee members have?
Documented conflicts include royalties from vaccine sales, consulting fees, corporate board seats at vaccine manufacturers, research funding from companies whose products members evaluate, speakers' bureau payments (described as "de facto marketers in academic robes"), paid travel, and endowed university chairs funded by pharmaceutical donations. Stanley Plotkin consulted for Merck, Pfizer, Sanofi, and GSK for decades. Paul Offit received approximately $6 million from Merck's RotaTeq sales.
What did three former medical journal editors say about pharmaceutical industry influence?
Richard Horton (The Lancet, 2004) said "journals have devolved into information laundering operations for the pharmaceutical industry." Richard Smith (BMJ, 25-year editor) said "medical journals are an extension of the marketing arm of pharmaceutical companies." Marcia Angell (New England Journal of Medicine) concluded "it is simply no longer possible to believe much of the clinical research that is published."
How did the Plotkin deposition demonstrate conflicts of interest?
Aaron Siri read Marcia Angell's description of conflicted individuals — those who "serve as consultants to the same companies whose products they evaluate, join corporate advisory boards and speakers bureaus, enter into patent and royalty arrangements, promote drugs and devices at company-sponsored symposia" — then walked Plotkin through each element, confirming point-by-point that Plotkin fit every criterion. Plotkin had no choice but to agree.
How does Julie Gerberding's career illustrate the revolving door?
Gerberding served as CDC Director from 2002 to 2009, overseeing recommendations for Merck's Gardasil and studies on Merck's MMR. She joined Merck as President of Vaccines in 2010 and cashed in over $22 million in Merck stock. A secretly recorded Pfizer director confirmed: "In the pharma industry, all the government officials who review our drugs eventually come work for pharma companies."
Is the conflicts of interest problem limited to individual corruption?
No. Aaron Siri argues the financial structure is self-reinforcing — scientists whose views align with pharma interests receive patronage and ascend, while those who deviate lose funding and stall. The result is that the entire leadership of vaccinology consists of people whose career success depended on pharmaceutical industry support. Siri calls this "pharma selection" — a systemic mechanism, not individual corruption.
This is the plain-HTML rendering of concepts/Conflicts of Interest.md, served for search
engines, AI crawlers, and accessibility tools. The interactive 3D version
of this wiki lives at vaccine-safety.org.